Konstantin B. Kolontarev

Konstantin B. Kolontarev

Auto-generated profile, based on publicly available information

Konstantin B. Kolontarev

Russian University of Medicine, Ministry of Health of Russia; S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare Departmen

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
DMDaria Matyushkina
Daria Matyushkina
VSVarvara Shokina
Varvara Shokina
PTPolina Tikhonova
Polina Tikhonova
Valentin ManuveraValentin Manuvera
Valentin Manuvera
DSDmitriy Shirokov
Dmitriy Shirokov
VGVadim Govorun
Vadim Govorun
COVID-19 caused by SARS-CoV-2 is continuing to spread around the world and drastically affect our daily life. New strains appear, and the severity of the course of the disease itself seems to be decreasing, but even people who have been ill on an outpatient basis suffer post-COVID consequences. Partly, it is associated with the autoimmune reactions, so debates about the development of new vaccines and the need for vaccination/revaccination continue. In this study we performed an analysis of the antibody response of patients with COVID-19 to linear and conformational epitopes of viral proteins using ELISA, chip array and western blot with analysis of correlations between antibody titer, disease severity, and complications. We have shown that the presence of IgG antibodies to the nucleoprotein can deteriorate the course of the disease, induce multiple direct COVID-19 symptoms, and contribute to long-term post-covid symptoms. We analyzed the cross reactivity of antibodies to SARS-CoV-2 with own human proteins and showed that antibodies to the nucleocapsid protein can bind to human proteins. In accordance with the possibility of HLA presentation, the main possible targets of the autoantibodies were identified. People with HLA alleles A01:01; A26:01; B39:01; B15:01 are most susceptible to the development of autoimmune processes after COVID-19.

1 January 2018 in Central European Journal of Urology
Verified
Journal Article
Open access
KKKonstantin Kolontarev
Konstantin Kolontarev
GKGeorge Kasyan
George Kasyan
DPDmitry Pushkar
Dmitry Pushkar
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...

1 January 2020 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Open access
LBL.A. Balykova
L.A. Balykova
OUOgarev Mordovia State University
Ogarev Mordovia State University
MGM.V. Granovskaya
M.V. Granovskaya
KZK.Y. Zaslavskaya
K.Y. Zaslavskaya
ESE.N. Simakina
E.N. Simakina
CSCity Clinical Hospital Named After S.I. Spasokukotsky
City Clinical Hospital Named After S.I. Spasokukotsky
Новые возможности направленной противовирусной терапии COVID-19: результаты многоцентрового клинического исследования эффективности и безопасности

1 January 2018 in Central European Journal of Urology
Verified
Journal Article
Open access
DPDmitry Pushkar
Dmitry Pushkar
AVAndrey Z. Vinarov
Andrey Z. Vinarov
LSLeonid Spivak
Leonid Spivak
KKKonstantin Kolontarev
Konstantin Kolontarev
MPMikhail Putilovskiy
Mikhail Putilovskiy
OEOleg Epstein
Oleg Epstein
Introduction In order to investigate the efficacy and safety of Afalaza in men with benign prostatic hyperplasia (BPH) at risk of progression, this multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to prostate-specific antigen (PSA) and endothelial nitric oxide synthase (eNOs), Afalaza was previously proved to modulate its molecular targets. The mechanism of action of the drug is associated with the modulating effect of the antibiodies (RA-Abs) on the molecular targets (PSA and eNOS) by way of conformational changes. Material and methods A total of 49 patients aged 45-60 years with BPH and moderate lower urinary tract symptoms (LUTS), total prostate volume (TPV) >= 30 cm(3), Qmax 10-15 ml/s, and serum PSA<4 ng/ml were randomly assigned to receive either Afalaza (n = 125) or placebo (n = 124) for 12 months. Changes in BPH/LUTS symptoms (according to the International Prostate Symptom Score), Qmax, TPV, PSA, BPH clinical progression, occurrence of acure urinary retention (AUR) events or BPH-related surgery were estimated as the study endpoints. Results IPSS mean change was -3.7 +/- 3.0 (95% CI -4.3 to -3.2) after 12 months of Afalaza (vs. -2.9 +/- 2.4; 95% CI -3.3 to -2.4 in placebo; p = 0.02). Qmax growth was 2.5 +/- 4.3 ml/s (vs. 1.4 +/- 3.3 in placebo; p = 0.049), TPV reduced by 11.8 +/- 16.0% (vs. 6.5 +/- 14.7%; p = 0.01, and PSA remained unchanged. Afalaza therapy resulted in a significant decrease in the total sum of BPH progression symptoms (p = 0.01). The maximum effect of Afalaza was registered after 12 months without a tendency to form a 'plateau'. During the study, no patients experienced AUR or BPH-related surgery. Conclusions A 12-month course of Afalaza therapy is effective and safe for patients with BPH. The results of end points measurements revealed asignificant advantage of Afalaza compared to placebo in the overall symptoms benefit and a decline in the risk of BPH progression.

9 March 2022 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
LBL. A. Balykova
L. A. Balykova
KZK. Ya. Zaslavskaya
K. Ya. Zaslavskaya
VPV. F. Pavelkina
V. F. Pavelkina
NPNikolay Pyataev
Nikolay Pyataev
NSN. M. Selezneva
N. M. Selezneva
DPD. Yu. Pushkar
D. Yu. Pushkar
Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to increase the efficacy of therapy in COVID-19 inpatients. This dosage form has expanded the possibilities of drug therapy in the inpatients, for whom a therapeutic effect acceleration and a high safety profile of the drugs used are especially important.The aim of the article is the evaluation of the efficacy and safety of a medicinal product containing favipiravir for the parenteral administration against the background of pathogenetic and symptomatic therapy, in comparison with standard therapy in hospitalized COVID-19 patients.Materials and methods. An open, randomized, multicenter comparative study was conducted in 6 research centers in the Russian Federation to evaluate the efficacy and safety of favipiravir, a lyophilisate for the preparation of a concentrate for the infusion solution administrated to the patients hospitalized with COVID-19. Screening procedures and randomization were completed in 217 patients, 209 of which had completed the study in accordance with the protocol.Results. Between the study groups, statistically significant differences have been found out, making it possible to consider the hypothesis of the drug Areplivir (favipiravir) superiority for the parenteral administration over the standard therapy, which included favipiravir (p. o.) and remdesivir. A comparative analysis has shown that a course of therapy with the parenteral favipiravir drug leads to a significant improvement in the condition of patients with COVID-19, significant benefits in terms of the speed and frequency of improvement in the clinical status of patients, as well as a reduction in the hospital stay length. It has been proven that therapy with a drug containing favipiravir for the parenteral administration does not adversely affect the parameters of clinical and biochemical blood tests, urinalysis, coagulograms, vital signs and ECG, which indicates the therapy safety. The study drug is characterized by a high safety profile and tolerability.Conclusion. The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need further studies of favipiravir to expand the range of its indications.

1 January 2020 in Infekcionnye bolezni
Verified
Journal Article
Closed access
LBL.A. Balykova
L.A. Balykova
AGA.V. Govorov
A.V. Govorov
AVA.O. Vasilyev
A.O. Vasilyev
ESE.N. Simakina
E.N. Simakina
S1Smolensk Smolensk Clinical Hospital No 1
Smolensk Smolensk Clinical Hospital No 1
DPD.YU. Pushkar
D.YU. Pushkar
This paper provides the results of a study evaluating the efficacy and safety of etiotropic therapy in patients hospitalized with SARS-CoV-2 infection. Objective. Тo evaluate the efficacy and safety of favipiravir (Areplivir) in patients with coronavirus disease 2019 (COVID-19) and compare it with recommended standard therapy. Patients and methods. Two hundred men and women aged between 18 and 80 years with COVID-19 were randomized into this study. The experimental group included patients who received favipiravir, whereas the control group comprised patients who received causal therapy in accordance with the latest version of the temporary methodical recommendations of the Ministry of Health of Russia ‘Prevention, diagnosis, and treatment of coronavirus infection (COVID-19).’ The efficacy and safety of therapy were evaluated by assessing clinical improvement using the WHO Ordinal Scale for Clinical Improvement, clinical and laboratory parameters, findings of chest computed tomography (CT), and elimination of SARS-CoV-2. We also analyzed the frequency and type of adverse events, need for invasive and non-invasive ventilation, and death rates. Results. Our analysis has demonstrated significant benefits of favipiravir over standard therapy in terms of the time to clinical improvement (in the experimental group it was 4 days shorter on average), time to recovery, frequency of recovery after 10 days (44% of patients from the experimental group and 10% of patients from the control group had no clinical signs of the disease at this time-point), and frequency of virus elimination by day 10 of therapy. Treatment with favipiravir was associated with a significant improvement in the lung condition (according to CT), normalization of laboratory parameters, and saturation level. Favipiravir has demonstrated a good safety profile similar to that of standard therapy. There was no difference in the frequency of adverse events between the experimental and control groups. Conclusion. The use of favipiravir for the treatment of SARS-CoV-2 infection reduced the time to clinical improvement by 4 days on average compared to standard therapy, ensured improvement of the lung condition (according to CT scans), and facilitated virus elimination in more than 90% of patients, thereby promoting faster recovery. Favipiravir had a good safety profile and was well tolerated by patients. This treatment regimen was shown to be effective, sufficient, and clinically reasonable to achieve good outcomes. Timely initiation of therapy with favipiravir (Areplivir) improves disease prognosis and reduces the global socioeconomic burden of the current pandemic. Key words: COVID-19, Areplivir, coronavirus, causal therapy, favipiravir